Roche
NEWS
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Xofluza showed a significant preventive effect after a single oral dose. Only about 1.9% of patients who received Xofluza showed signs of the flu, compared to 13.6% of the placebo group.
Companies share robust oncology data at annual ASCO meeting.
Synlogic is partnering with Roche to develop Synlogic’s SYNB1891 with Roche’s checkpoint inhibitor Tecentriq (atezolizumab) in advanced solid tumors.
CinCor plans to advance the therapeutic through proof-of-concept Phase II clinical trials in treatment resistant hypertension and primary aldosteronism.
The companies said they planned to give the government additional time to review the deal. This is the third delay.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.
JOBS
IN THE PRESS